l’Ami MJ, et al. - Herein authors investigated if patients with rheumatoid arthritis with adalimumab concentrations >8μg/mL could prolong their dosing interval by 50% without a clinically relevant change in disease activity. Findings suggested that the standard dosing interval could be prolonged to once every 3 weeks by adalimumab-treated patients with RA, without loss of disease control.